《睡眠專業人士雜誌》
星期四, 七月 23, 2026
Vapotherm, Inc. announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This next-generation system is designed to provide high-velocity therapy using an integrated air source, eliminating the need for wall air or any pressurized air source. It is estimated that 50% of U.S. […]
Masimo announced the U.S. introduction of softFlow®, innovative pulmonary care therapy which provides nasal high-flow warmed and humidified respiratory gases to spontaneously breathing patients. The technology, available on the softFlow 50, offers adult patients high-flow respiratory support through a soft nasal cannula by generating a consistent high flow of warm, humidified […]
The Servo-air® ventilator, for use in adult and pediatric patients, is designed to be mobile and easy to use and is available now in the U.S. The new ventilator addresses multiple needs of COVID-19 treatment centers including mobility and flexibility, by being independent of wall-based gas units, possessing a hot-swappable […]
Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients suffering from respiratory distress, announced a major expansion in its capital equipment manufacturing capabilities. This expansion is expected to enable the company to increase production […]
Vapotherm, Inc. has announced that the FDA recently granted Breakthrough Device Designation for the Company’s Oxygen Assist Module (OAM). FDA’s Breakthrough Device Program is intended to help patients and healthcare providers receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis of […]
